Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

Company Financials: Orthopaedics and Spine

Kensey Nash (for 2Q12, ended 12/31/11)
$11.9MM, +148%*
    
Spine $5.0MM, +154%
     Sports Medicine $3.2MM, +20%
     Trauma & Craniomaxillofacial $3.7MM, +1,750% (Norian products $3.6MM)
*Growth includes acquisitions.

  • Excluding sales from Norian acquisition: $7.4MM, +53%
  • Royalties from Stryker, $1.4MM, +7%
  • Stryker selling Vitoss ex-U.S., primarily through spine group, with plans to sell throughout other segments; salesforce integration and training in about the "4th inning"
  • Will continue to combine ceramic and collagen materials to develop future products with current and new customers

Life Spine
+29%

  • Growth driven by increased demand for Centric MIS platform, expansion into 10 ex-U.S. markets, etc.

Medicrea
€19.1MM (~US $24.7MM), +5%

4Q11 revenue: €4.1MM ($5.4MM)

  • Strengthening ex-U.S. sales structure, specifically in France

Ossur
Bracing & Support $211.1MM, +15%

4Q11 revenue: $52MM, +8%

  • All bracing/support products from U.S. now manufactured at facility in Mexico
  • Unloader One brace performing well in EMEA region

RSB Spine
+46%

  • Growth attributed to efforts of distributor Paradigm BioDevices, growing surgeon acceptance of modular standalone fusion offering

4 COMMENTS

Security code
Refresh